Ad
related to: ranbaxy product list with price
Search results
Results From The WOW.Com Content Network
Ranbaxy's Malvinder Singh remained as CEO after the transaction. [11] The addition of Ranbaxy Laboratories extended Daiichi-Sankyo's operations, with the combined company worth about US$30 billion. [12] In 2009, it was reported that former Novartis Senior Vice-President Yugal Sikri would lead the Indian operations of Ranbaxy Laboratories. [13] [14]
Prescription drug list prices in the United States continually are among the highest in the world. [1] [2] The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015.
Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Calcutta, West Bengal with five psychiatry products and a two-person marketing team. Today it is ranked number one in share of prescriptions with 12 classes of doctors in India and a market leader in Psychiatry, Neurology, Cardiology, Orthopaedics, Gastroenterology, Nephrology, Diabetology, Dermatology, Urology ...
For premium support please call: 800-290-4726 more ways to reach us
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Volini is a brand of pain relief medical spray and cream manufactured, marketed and sold by Sun Pharma in India. [1] [2] The product was created by Ranbaxy Laboratories, but has been owned by Sun Pharma ever since Ranbaxy was acquired by the latter in 2014. [3]
In 2013, in order to market its products in USA, Alembic Pharmaceuticals entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc. (Ranbaxy). [ 6 ] In 2014, Alembic Pharmaceuticals through its wholly owned subsidiary – Alembic Global Holdings, got into joint ventures with Adwiya Mami SARL Algeria and expanded its market in ...
On June 10, 2008, the company agreed to take a majority (64%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion. [13] [14] It acquired U3 Pharma in June 2008, contributing a therapeutic anti-HER3 antibody to the company's anticancer portfolio. [15] The company closed U3 Pharma in 2015. [16]